MA27183A1 - Composes oxo-azabicycliques - Google Patents
Composes oxo-azabicycliquesInfo
- Publication number
- MA27183A1 MA27183A1 MA27842A MA27842A MA27183A1 MA 27183 A1 MA27183 A1 MA 27183A1 MA 27842 A MA27842 A MA 27842A MA 27842 A MA27842 A MA 27842A MA 27183 A1 MA27183 A1 MA 27183A1
- Authority
- MA
- Morocco
- Prior art keywords
- group
- atom
- description
- chosen
- inclusive
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 102000005741 Metalloproteases Human genes 0.000 abstract 1
- 108010006035 Metalloproteases Proteins 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 239000002585 base Substances 0.000 abstract 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 abstract 1
- 229940126534 drug product Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000004426 substituted alkynyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
DEPOSANT Société dite: WARNER-LAMBERT COMPANY LLC REVENDICATION DE PRIORITES WO 8 Mars 2002 PCT/EP02/03240 Voir en annexe le titre de l'invention et le texte de l'abrégé Composés oxo-azabicycliques Un composé choisi parmi ceux de formule (I) dans laquelle : X1, X2 et X3 représentent des atomes de N ou des groupes -CR3 dans lesquels R3 est tel que défini dans la description, G1 représente un groupe choisi parmi ceux de formules (i/a) et (i/b) dans lesquelles R4, R5 et R6 sont tels que définis dans la description, G2 représenté un groupe choisi entre une triple liaison carbone-carbone, un groupe -CH=C=CH-, un groupe C=O, un groupe C=S, un groupe S(O)n1 dans lequel n1 représente un nombre entier de 0 à 2 inclus, ou un groupe de formule (i/c) dans laquelle Y1 représente un atome de O, un atome de S, un groupe -NH ou un groupe -N-alkyle, et Y2 représente un atome de O, un atome de S, un groupe -NH, ou un groupe -N-alkyle, n représente un nombre entier de 0 à 6 inclus et m représente un nombre entier de 0 à 7 inclus, Z1 représente un groupe -CR9R10, dans lequel R9 et R10 sont tels que définis dans la description, A représente un système cyclique, R1 représente un groupe choisi entre H, des groupes alkyle, alcényle et alcynyle facultativement substitués et le groupe de formule (i/d) dans laquelle p, Z2, B, q et G3 sont tels que définis dans la description et, facultativement, ses isomères optiques, son N-oxyde et ses sels d'addition formés avec un acide ou une base pharmaceutiquement acceptable, et des produits médicamenteux le contenant sont utiles comme inhibiteurs spécifiques de la métalloprotéase de matrice de type 13.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2002/003240 WO2003076416A1 (fr) | 2002-03-08 | 2002-03-08 | Composes oxo azabicycliques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27183A1 true MA27183A1 (fr) | 2005-01-03 |
Family
ID=27798761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA27842A MA27183A1 (fr) | 2002-03-08 | 2004-08-31 | Composes oxo-azabicycliques |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1492775A2 (fr) |
| JP (1) | JP2005526070A (fr) |
| KR (1) | KR20040095270A (fr) |
| CN (1) | CN1738806A (fr) |
| AP (1) | AP2004003125A0 (fr) |
| AR (1) | AR039562A1 (fr) |
| AU (2) | AU2002249275A1 (fr) |
| BR (1) | BR0308280A (fr) |
| CA (1) | CA2478706A1 (fr) |
| CO (1) | CO5601020A2 (fr) |
| EA (1) | EA200401053A1 (fr) |
| EC (1) | ECSP045278A (fr) |
| IL (1) | IL163818A0 (fr) |
| IS (1) | IS7414A (fr) |
| MA (1) | MA27183A1 (fr) |
| MX (1) | MXPA04008681A (fr) |
| NO (1) | NO20044041L (fr) |
| OA (1) | OA12782A (fr) |
| PA (1) | PA8568501A1 (fr) |
| PE (1) | PE20031018A1 (fr) |
| PL (1) | PL372622A1 (fr) |
| SV (1) | SV2003001495A (fr) |
| TN (1) | TNSN04169A1 (fr) |
| UY (1) | UY27700A1 (fr) |
| WO (2) | WO2003076416A1 (fr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8539501A1 (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Compuestos triazolo como inhibidores de mmp |
| US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
| US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| MXPA05001786A (es) | 2002-08-13 | 2005-04-25 | Warner Lambert Co | Derivados de azaisoquinolina como inhibidores de la metaloproteinasa de matriz. |
| AU2003249540A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
| WO2004014909A1 (fr) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Derives fusionnes de la tetrahydropyridine inhibiteurs de la metalloprotease matricielle |
| WO2004014892A1 (fr) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Derives monocycliques en tant qu'inhibiteurs de metalloproteinases matricielles |
| JP2006500351A (ja) | 2002-08-13 | 2006-01-05 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | マトリックスメタロプロテアーゼ−１３阻害剤としてのピリミジン−２，４−ジオン誘導体 |
| WO2004014923A1 (fr) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Inhibiteurs de metalloprotease bicycliques condenses avec la pyrimidinone |
| AU2003250466A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
| WO2004014384A2 (fr) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Composes cycliques contenant des groupes liant le zinc en tant qu'inhibiteurs de metalloprotease de matrice |
| AU2003253150A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Chromone derivatives as matrix metalloproteinase inhibitors |
| PA8578101A1 (es) | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
| WO2005016926A1 (fr) * | 2003-08-19 | 2005-02-24 | Warner-Lambert Company Llc | Derives de pyrido[3,4-d]pyrimidine utiles comme inhibiteurs de la metalloproteinase-13 de matrice |
| DE10360835A1 (de) * | 2003-12-23 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel |
| CN1976907A (zh) * | 2004-04-30 | 2007-06-06 | 武田药品工业株式会社 | 杂环酰胺化合物及其作为mmp－13抑制剂的用途 |
| CA2568756A1 (fr) * | 2004-06-15 | 2005-12-29 | Astrazeneca Ab | Quinazolones substitues en tant qu'agents anticancereux |
| CN101522676A (zh) | 2006-10-05 | 2009-09-02 | Cv医药有限公司 | 用作硬脂酰-CoA脱氢酶抑制剂的双环含氮杂环化合物 |
| WO2012052451A1 (fr) | 2010-10-18 | 2012-04-26 | Merz Pharma Gmbh & Co. Kgaa | Modulateurs des récepteurs métabotropes au glutamate |
| CN103524431B (zh) * | 2013-09-24 | 2016-01-13 | 西安交通大学 | 3-苄基-4-喹唑啉酮类化合物及其合成方法和应用 |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| KR102703498B1 (ko) | 2015-09-23 | 2024-09-04 | 얀센 파마슈티카 엔브이 | 신규 화합물 |
| CN108137546B (zh) | 2015-09-23 | 2021-07-27 | 詹森药业有限公司 | 双杂芳基取代的1,4-苯并二氮杂卓化合物及其用于治疗癌症的用途 |
| FR3046793B1 (fr) * | 2016-01-14 | 2018-01-05 | Les Laboratoires Servier | Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5380398A (en) * | 1996-12-17 | 1998-07-15 | E.I. Du Pont De Nemours And Company | Fungicidal quinazolinones |
| PA8539401A1 (es) * | 2001-02-14 | 2002-10-28 | Warner Lambert Co | Quinazolinas como inhibidores de mmp-13 |
| PA8539301A1 (es) * | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Inhibidores de la metaloproteinasa de la matriz |
-
2002
- 2002-03-08 AU AU2002249275A patent/AU2002249275A1/en not_active Abandoned
- 2002-03-08 WO PCT/EP2002/003240 patent/WO2003076416A1/fr not_active Ceased
-
2003
- 2003-03-04 SV SV2003001495A patent/SV2003001495A/es not_active Application Discontinuation
- 2003-03-06 EP EP03708181A patent/EP1492775A2/fr not_active Withdrawn
- 2003-03-06 PE PE2003000218A patent/PE20031018A1/es not_active Application Discontinuation
- 2003-03-06 CA CA002478706A patent/CA2478706A1/fr not_active Abandoned
- 2003-03-06 AP APAP/P/2004/003125A patent/AP2004003125A0/en unknown
- 2003-03-06 AR ARP030100749A patent/AR039562A1/es not_active Application Discontinuation
- 2003-03-06 JP JP2003574636A patent/JP2005526070A/ja not_active Withdrawn
- 2003-03-06 WO PCT/EP2003/002277 patent/WO2003076417A2/fr not_active Ceased
- 2003-03-06 CN CNA038048752A patent/CN1738806A/zh active Pending
- 2003-03-06 EA EA200401053A patent/EA200401053A1/ru unknown
- 2003-03-06 IL IL16381803A patent/IL163818A0/xx unknown
- 2003-03-06 BR BR0308280-6A patent/BR0308280A/pt not_active IP Right Cessation
- 2003-03-06 OA OA1200400234A patent/OA12782A/en unknown
- 2003-03-06 UY UY27700A patent/UY27700A1/es not_active Application Discontinuation
- 2003-03-06 AU AU2003212307A patent/AU2003212307A1/en not_active Abandoned
- 2003-03-06 MX MXPA04008681A patent/MXPA04008681A/es unknown
- 2003-03-06 PA PA20038568501A patent/PA8568501A1/es unknown
- 2003-03-06 KR KR10-2004-7013994A patent/KR20040095270A/ko not_active Ceased
- 2003-03-06 PL PL03372622A patent/PL372622A1/xx not_active Application Discontinuation
-
2004
- 2004-08-19 IS IS7414A patent/IS7414A/is unknown
- 2004-08-25 CO CO04082792A patent/CO5601020A2/es not_active Application Discontinuation
- 2004-08-31 MA MA27842A patent/MA27183A1/fr unknown
- 2004-09-03 EC EC2004005278A patent/ECSP045278A/es unknown
- 2004-09-03 TN TNP2004000169A patent/TNSN04169A1/fr unknown
- 2004-09-24 NO NO20044041A patent/NO20044041L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20044041L (no) | 2004-10-07 |
| TNSN04169A1 (fr) | 2007-03-12 |
| WO2003076416A1 (fr) | 2003-09-18 |
| ECSP045278A (es) | 2004-10-26 |
| MXPA04008681A (es) | 2004-12-06 |
| KR20040095270A (ko) | 2004-11-12 |
| PL372622A1 (en) | 2005-07-25 |
| OA12782A (en) | 2006-07-10 |
| IL163818A0 (en) | 2005-12-18 |
| AP2004003125A0 (en) | 2004-09-30 |
| EA200401053A1 (ru) | 2005-04-28 |
| IS7414A (is) | 2004-08-19 |
| AU2002249275A1 (en) | 2003-09-22 |
| EP1492775A2 (fr) | 2005-01-05 |
| PE20031018A1 (es) | 2004-01-09 |
| AU2003212307A1 (en) | 2003-09-22 |
| CN1738806A (zh) | 2006-02-22 |
| JP2005526070A (ja) | 2005-09-02 |
| BR0308280A (pt) | 2004-12-28 |
| AR039562A1 (es) | 2005-02-23 |
| UY27700A1 (es) | 2003-10-31 |
| PA8568501A1 (es) | 2003-12-19 |
| SV2003001495A (es) | 2003-11-04 |
| WO2003076417A2 (fr) | 2003-09-18 |
| CO5601020A2 (es) | 2006-01-31 |
| CA2478706A1 (fr) | 2003-09-18 |
| WO2003076417A3 (fr) | 2003-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN04169A1 (fr) | Composes oxo-azabicycliques | |
| CA2481461A1 (fr) | Derives de n-[phenyl(piperidin-2-yl) methyl] benzamide, leur preparation et leur application en therapeutique | |
| MA26989A1 (fr) | Derives de pyridine inhibiteurs de metalloproteinases de matrice | |
| MA27439A1 (fr) | Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase | |
| MA27774A1 (fr) | Inhibiteurs de phosphatidylinositol 3-kinase | |
| LU90011I2 (fr) | Remifentanil facultativement sous la forme d'un sel d'addition d'acide pharmaceutiquement acceptable y compris le chlorhydrate de remifentanil | |
| MA56883B1 (fr) | Dérivés de 2-hydroxycycloalcane-1-carbamoyle | |
| MA30014B1 (fr) | Derives spirocycliques | |
| TNSN08270A1 (fr) | Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale | |
| MA27573A1 (fr) | Sinomenine et derives de sinomenine, synthese et utilisation. | |
| CA2496040A1 (fr) | Derives de carbamates de dioxan-2-alkyle, methode de preparation connexe et utilisation desdits derives en therapeutique | |
| MXPA04003192A (es) | Sales de acido succinico de 5, 7, 14-triazatetraciclo ?10.3.1.02,11.04,9? -hexadeca-2(11), 3, 5, 7, 9-pentaeno y composiciones farmacetucias de las mismas. | |
| MA27135A1 (fr) | Agents antidiabetiques oraux | |
| MA57000B1 (fr) | Dérivés d'alpha-d-galactopyranoside | |
| MA31674B1 (fr) | Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique | |
| CA3156269A1 (fr) | Inhibiteurs de facteur d du complement oral | |
| MA26858A1 (fr) | Acides ox(adi)azolyl-hydroxamiques utiles comme inhibiteurs de procollagene c-proteinase. | |
| MA26953A1 (fr) | Derives de pipérazine pontés. | |
| MA27887A1 (fr) | Dicetopiperazines substituees et leur utilisation comme antagonistes de l'ocytocine | |
| MA27712A1 (fr) | Triazoles utiles en therapeutique | |
| CA2489723A1 (fr) | Nouveaux derives d'aryl-{4-halogeno-4-[(heteroaryl-methylamino)-methyl]-piperidin-1-yl}-methanone, leur procede de preparation et leur utilisation a titre de medicaments | |
| CA2225780A1 (fr) | Nouveaux derives de n-benzylpiperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| MA27795A1 (fr) | Derives d'amine cycliques, procedes de preparation de ceux-ci et compositions pharmaceutiques les contenant | |
| CA2231025A1 (fr) | Nouveaux composes de 2-amino indane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| FR2859208B1 (fr) | Nouveaux derives de 9-amino-podophyllotoxine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |